Trial
NCT03292133
A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Massachusetts General Hospital
Collaborators
Novartis
Condition
Lung Cancer
Intervention
EGF816
Why stopped
Slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-06-10